Critically ill Covid-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said on Sunday.
Japanese drug-discovery company PeptiDream Inc. will collaborate with Merck & Co. in developing COVID-19 therapies.
Ligandal is reportedly the only company developing a prospective “antidote” and vaccine in a single platform for COVID-19, with an approach that could actually help eliminate the virus from an already-infected host, while also bolstering the immune response.
A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.
Harmony Biosciences snagged approval from the U.S. FDA for the company’s first commercial product, a treatment for narcolepsy.
Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.
Peptidream Inc. scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment of multiple disease targets.
Janssen Pharmaceuticals, a division of healthcare giant Johnson & Johnson, and Tokyo-based Peptidream will develop peptide-based therapies to target multiple metabolic and cardiovascular targets.
La Jolla Pharmaceutical Co.’s shares surged after the company said its drug to treat low blood pressure succeeded in a key trial.